Alternate Health Corp. Announces Completion of Initial Study to Treat Zika Virus Symptoms with Hemp-Derived Cannabinoid
Shared by THCbiz.com
TORONTO, May 16, 2017 /PRNewswire/ – Alternate Health Corp. (CSE:AHG, OTC:AHGIF), a diverse healthcare company revolutionizing patient care and research through compliance and technology in the emerging medical cannabis industry, announced today the completion of its initial study to demonstrate the effectiveness of cannabinoid in treating chronic post-Zika virus symptoms.
The study, conducted at the Neubauer Hyperbaric Neurologic Center, evaluated the effectiveness of combining treatment with hyperbaric oxygen (HBO) and industrial hemp-derived cannabinoid to alleviate the rare but debilitating chronic post-Zika infection symptoms of pain, fatigue, anxiety, depressive state, and loss of appetite.
The Zika virus is a flavivirus transmitted by mosquitos, and over the past 10 years has caused infection in more than 50 countries worldwide. Zika has been declared a pandemic and is considered a Public Health Emergency by the World Health Organization. The Centers for Disease Control and Prevention (CDC) has confirmed there is scientific consensus that Zika causes birth defects, and reports have linked its infection to an infrequent but serious neurological condition, Guillain-Barré Syndrome.
Although acute Zika infection is usually self-limiting, some patients can experience prolonged periods of severe fatigue, joint pain, loss of appetite, anxiety, depressive state, and lethargy after clearance of acute viral symptoms. It is these symptoms in this subset of Zika-infected patients that Alternate Health evaluated in its initial cannabinoid-based, Institutional Review Board (IRB) approved research study.
Continue reading at THCbiz.com
Don’t forget to like WeedTV @yourweedtv